Fluconazole 150 mg single dose versus itraconazole 200 mg per day for 3 days in the treatment of acute vaginal candidiasis: a double-blind randomized study
- 作者：De Punzio ; Cosima ; Garutti ; Paola ; Mollica ; Gioachino ; Nappi ; Carmine ; Piccoli ; Roberto ; Genazzani ; Andrea Riccardo
- 关键词：Vaginal candidiasis ; Fluconazole ; Itraconazole
- 刊名：European Journal of Obstetrics and Gynecology and Reproductive Biology
- 出版年：2003
- 期刊代码：92_03012115
- 类别：med
- 出版时间：February 10, 2003
- 卷：106
- 期：2
- 页码：193-197
- 文件大小：206 K
摘要
Objective: To compare the safety and efficacy of fluconazole 150mg single dose and itraconazole 200mg per day for 3 days in the treatment of the acute episode of vulvovaginal candidiasis (VVC). Methods: Double-blind randomized study conducted in three University centers. Patients with acute clinically and mycologically confirmed VVC were enrolled. Results: A total of 86 patients were enrolled; of them, 38 fluconazole and 32 itraconazole patients were evaluable. At the Day 7 visit, all but one fluconazole patients were cured or improved with eradication of the baseline pathogen obtained in all but two itraconazole patients. At the Day 21 visit, a 13%relapse rate was observed in both groups with all other patients cured or improved; eradication rates were 76%for fluconazole and 66%for itraconazole. Global symptom scores (GSS) were significantly more severe at baseline in fluconazole patients (P=0.003). Nevertheless, the slope of the GSS decrease between baseline and Day 7 was similar for both groups whilst GSS were identical at the last visit. Nineteen fluconazole patients reported 31 adverse events and 15 itraconazole patients reported 30 adverse events. Conclusions: Both oral antifungal treatments showed good clinical and mycological efficacy on the acute episode of VVC with a dramatic decrease of signs and symptoms 7 days after treatment initiation. Fluconazole in single dose warrants optimal compliance in patients who frequently experience more than one episode of VVC.